Gossamer Bio, Inc.

For the period ended Sep 30, 2026. Filed Nov 10, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 10, 2026

GOSS$11.28+6.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity (Deficit

(in thousands, except share amounts)

Common stock · Additional paid-in capital · Accumulated deficit · Accumulated other comprehensive income (loss) · Total stockholders' equity (deficit)
Shares · Amount
Balance as of December 31, 2025	2,920,964	$—	$1,321,327	$(1,438,938)	$(5,149)		$(122,760)
Exercise of stock options	2,643	—	220	—	—		220
Stock-based compensation	—	—	6,304	—	—		6,304
Issuance of common stock pursuant to Employee Stock Purchase Plan	10,097	—	292	—	—		292
Net loss	—	—	—	(46,664)	—		(46,664)
Other comprehensive income	—	—	—	—	1,125		1,125
Balance as of March 31, 2026	2,933,704	$—	$1,328,143	$(1,485,602)	$(4,024)		$(161,483)
Stock-based compensation	—	—	2,463	—	—		2,463
Issuance of common stock and warrants in connection with the exchange of the 2027 Notes, net of issuance costs	3,176,881	1	47,800	—	—		47,801
Net income	—	—	—	16,900	—		16,900
Other comprehensive income	—	—	—	—	290		290
Balance as of June 30, 2026	6,110,585	$1	$1,378,406	$(1,468,702)	$(3,734)		$(94,029)
Reclassification of Purchase Warrants liability to Additional Paid-in Capital	—	—	15,330	—	—		15,330
Stock-based compensation	—	—	3,791	—	—		3,791
Issuance of common stock pursuant to Employee Stock Purchase Plan	5,734	—	66	—	—		66
Issuance of common stock for fractional shares in connection with the reverse stock split	71	—	—	—	—		—
Net loss	—	—	—	(48,072)		(48,072)
Other comprehensive income	—	—	—	—	119		119
Balance as of September 30, 2026	6,116,390	$1	$1,397,593	$(1,516,774)	$(3,615)		$(122,795)

Common stock · Additional paid-in capital · Accumulated deficit · Accumulated other comprehensive income (loss) · Total stockholders' equity (deficit)
Shares · Amount
Balance as of December 31, 2024	2,832,552	$—	$1,296,871		$(1,268,568)	$1,189	$29,492
Exercise of stock options	1,408	—	132		—	—	132
Stock-based compensation	—	—	2,405		—	—	2,405
Issuance of common stock pursuant to Employee Stock Purchase Plan	6,306	—	372		—	—	372
Net loss	—	—	—		(36,638)	—	(36,638)
Other comprehensive loss	—	—	—		—	(2,013)	(2,013)
Balance as of March 31, 2025	2,840,266	$—	$1,299,780		$(1,305,206)	$(824)	$(6,250)
Vesting of restricted stock	—	—	—		—	—	—
Exercise of stock options	1,266	—	94		—	—	94
Stock-based compensation	—	—	2,586		—	—	2,586
Net loss	—	—	—		(38,273)	—	(38,273)
Other comprehensive loss	—	—	—		—	(4,264)	(4,264)
Balance as of June 30, 2025	2,841,532	$—	$1,302,460		$(1,343,479)	$(5,088)	$(46,107)
Investment in merger option through issuance of stock	31,250	—	7,476		—	—	7,476
Exercise of stock options	5,479	—	465		—	—	465
Exercise of warrants	5,748	—	938		—	—	938
Stock-based compensation	—	—	2,666		—	—	2,666
Issuance of common stock pursuant to Employee Stock Purchase Plan	7,317	—	469		—	—	469
Net loss	—			(48,221)		(48,221)
Other comprehensive loss	—	—	—		—	(19,000)	(19)
Balance as of September 30, 2025	2,891,326	$—	$1,314,474		$(1,391,700)	$(5,107)	$(82,333)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.